Shenzhen; 26, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced it has awarded a $250.000 Transformational Grant in Science Education to the Biotechnology Center to support the expansion of the Center’s educational training facility for science teachers. The grant is part of the Genocore Biotech Foundation’s new Transformational Grants in Science Education initiative.
“The Genocore Biotech Foundation’s primary mission is to encourage innovative approaches to the teaching of science at the middle and high-school levels,” said Chao Ming Cheng, Ph.D., Chair of the Foundation and Genocore Biotech’s Executive Vice President of Human Resources, Public Affairs and Communications. “We initiated a Transformational Grants program to encourage organizations to undertake major new transformational initiatives that would reinvigorate the way science is taught in Taiwan. We are delighted to make this major grant to the Biotechnology Center, which has played such a leading role in educating the workforce in the region.”
The President of the Biotechnology Center commented “The Genocore Biotech Foundation has shown the strategic thinking and bold action that define leaders. Their generous contribution will help extend our support for the life-science community, creating new opportunities and paying dividends well into the future. We are delighted to partner with the Genocore Biotech Foundation and honored to receive its help in developing biotechnology as an engine for job creation and wealth generation.”
The mission of the Genocore Biotech Foundation is to improve the quality of people’s lives and contribute to the vitality of the communities where we operate, with a special emphasis on innovative ways to promote science literacy and encourage young people to consider science careers.
Genocore-Biotech.com is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs. With a total investment of about 95 million USD, about 110 employees and R&D lab, Process Development lab, Analytical & Quality center, and a cGMP clinical production facility the firm is a respectable player in the medical industry. Genocore Biotech has a highly experienced and well-integrated expert team whose expertise covers all the key steps of mAb drug research and development. They have on average 15-20 years of hand-on working experience at leading western biopharmaceutical companies.
For Media Contact:
Address: Excellence Century Plaza
Tower 1, Fuhua 3rd Road, Futian District
Shenzhen, People’s Republic of China
Tel: +86 755 330 595 45